The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has implemented the International Recognition Procedure (IRP) starting January 1, 2024.
The IRP is designed to streamline the registration of pharmaceutical products in the UK by considering the expertise and decision-making of trusted regulatory partners who have already authorised the product. The countries and regions covered by this procedure include Australia, Canada, the European Union, Japan, Switzerland, Singapore, and the United States.
The introduction of the IRP marks a significant milestone in the UK’s post-Brexit strategy for approving medicines. The IRP is a strategic response to the dynamic global environment of life sciences and medicine advancement, aiming to maintain the UK’s appeal as a focal point for pharmaceutical innovation and to guarantee patient access to cutting-edge treatments.
𝐓𝐡𝐞 𝐚𝐝𝐨𝐩𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐥𝐢𝐚𝐧𝐜𝐞 𝐩𝐫𝐨𝐜𝐞𝐝𝐮𝐫𝐞 𝐢𝐬 𝐚𝐧𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞𝐝 𝐭𝐨 𝐞𝐧𝐡𝐚𝐧𝐜𝐞 𝐭𝐡𝐞 𝐩𝐚𝐜𝐞 𝐚𝐧𝐝 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞𝐧𝐞𝐬𝐬 𝐨𝐟 𝐞𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐧𝐠 𝐧𝐞𝐰 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐔𝐊. 𝐋𝐞𝐯𝐞𝐫𝐚𝐠𝐢𝐧𝐠 𝐞𝐱𝐢𝐬𝐭𝐢𝐧𝐠 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 𝐟𝐫𝐨𝐦 𝐫𝐞𝐥𝐢𝐚𝐛𝐥𝐞 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐬, 𝐭𝐡𝐞 𝐈𝐑𝐏 𝐬𝐭𝐫𝐢𝐯𝐞𝐬 𝐭𝐨 𝐞𝐱𝐩𝐞𝐝𝐢𝐭𝐞 𝐭𝐡𝐞 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐨𝐟 𝐬𝐚𝐟𝐞 𝐚𝐧𝐝 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐢𝐨𝐮𝐬 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐟𝐨𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐔𝐊.
Sources:
- International Recognition Procedure. United Kingdom: Medicines and Healthcare products Regulatory Agency. Dec 20 2023. Available from: https://www.gov.uk/government/publications/international-recognition-procedure/international-recognition-procedure (Accessed 04 Jan 2024)
- Medicines and Healthcare products Regulatory Agency. MHRA’s new International Recognition Procedure (IRP) goes live from 1 January 2024. GOV.UK. Jan 2 2023. Available from: https://www.gov.uk/government/news/mhras-new-international-recognition-procedure-irp-goes-live-from-1-january-2024 (Accessed 04 Jan 2024)